Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.36

+2.0%

Nov 26 2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bladerunner17 who wrote (155)	1/23/2018 4:15:14 PM
From: scaram(o)uche	of 294

That's right, I should look at the bright side. He's the very best that a bunch of Vancouver-traded biotechs could buy. What percentage of the current market caps of ProMIS, Diamedica and Sernova, when added together, is equal to his salary, bonus and options during that stellar 25 year career? Look at that last release.... "has held multiple academic and industry appointments, most recently at Ariad Pharmaceuticals, Epizyme Inc. and Medpace." Does that impress you? "has been involved in the success of products such as Rituxan®, Avastin®, Zelboraf® and Herceptin®" So have a bunch of UPS drivers. Losing competitive advantage daily.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next